Dollar, money

J&J Restructure: Will Cost Cuts Affect Suppliers?

By MedTech Intelligence Staff
No Comments
Dollar, money

The company just announced that it is restructuring its global supply chain.

This morning Bloomberg is reporting that Johnson & Johnson has raised its sales forecast, but with it comes a restructuring of its global supply chain. The plan could generate up to $800 million in annual pretax savings by 2022, and the restructure could affect J&J’s suppliers, according to Bloomberg.

Seeking Alpha reports that several suppliers have exposure to this plan, including Universal Biosensors, Stereotaxis, Stratasys, Tokyo Automatic Machinery, Samsung Biologics and Charles River Labs.

Leave a Reply

Your email address will not be published. Required fields are marked *